Page last updated: 2024-08-17

ethinyl estradiol and maraviroc

ethinyl estradiol has been researched along with maraviroc in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA	1

Trials

1 trial(s) available for ethinyl estradiol and maraviroc

Article	Year
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. British journal of clinical pharmacology, 2008, Volume: 65 Suppl 1 Topics: Adolescent; Adult; Anti-Anxiety Agents; Anti-HIV Agents; CCR5 Receptor Antagonists; Contraceptives, Oral; Cyclohexanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; HIV Infections; Humans; Lamivudine; Levonorgestrel; Male; Maraviroc; Midazolam; Middle Aged; Statistics as Topic; Triazoles; Zidovudine	2008

Article

Year

Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

British journal of clinical pharmacology, 2008, Volume: 65 Suppl 1

Topics: Adolescent; Adult; Anti-Anxiety Agents; Anti-HIV Agents; CCR5 Receptor Antagonists; Contraceptives, Oral; Cyclohexanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; HIV Infections; Humans; Lamivudine; Levonorgestrel; Male; Maraviroc; Midazolam; Middle Aged; Statistics as Topic; Triazoles; Zidovudine

2008

Other Studies

2 other study(ies) available for ethinyl estradiol and maraviroc

Article	Year
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3 Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.

Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs

2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013